Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Sister Fund to USA-Based Biotech Focused Investment Firm Invests Up to $20M in Therapeutics, Medical Devices with Strong China Angle

14 Jun

A newly established sister fund to a USA based biotech focused fund looks to fund companies either based in China or with a strong China angle. The firm will invest 60-70% of its funds in therapeutics, with the rest in medical devices. For most of its investments, the firm will invest around $20M in Seed to Series A rounds for a majority stake in the company, in addition to taking active part in the company. Occasionally, the firm will make a minority investment in a company, no later than Series B, but is by no means a passive investor. The firm is looking for companies with technologies either in development or in clinical trials, unless based in China, in which case the company’s lead candidate must already be in clinical trials.

While fairly agnostic to subsector and indication, the firm is interested in therapeutics and medical devices that are relevant to the Chinese market. Of particular interest are technologies related to oncology indications common to China, ophthalmic indications, neurodegenerative diseases, and women’s health and fertility.

The firm is looking to take a majority share in most of its portfolio companies, followed by active involvement in company management. In all cases the firm looks to be an active investor. The company must have a China angle, whether it has headquarters or offices there, or is pursuing the Chinese market or clinical trials in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA Venture Firm Seeks to Invest in Innovative Digital Health and Software-Based Diagnostic Companies

14 Jun

A venture capital firm with multiple offices in the USA is looking to invest in tech-driven companies that have at least one female on the leadership team. The firm invests in technology companies, including those in the healthcare sector, such as digital health and software-based diagnostics companies. The firm will invest primarily in series A-B rounds in USA-based companies with at least $1M in revenue. The firm will typically make initial investments between $1.5-5M.

The firm invests in technology companies in the digital health space that are solving some of the world’s greatest challenges. The firm particularly likes to see companies that are creating more affordable health solutions.

The firm does not require a board seat when investing, but may take one if the firm leads an investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Japanese Pharmaceutical with Established USA Subsidiary Seeks Innovative Early-Stage Therapeutics Assets in Neurodegenerative & Neurodevelopmental Diseases

14 Jun

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. The pharma also has a large USA-based subsidiary. Sponsored research may also be considered with a focus on Japan-based academic institutions.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS/neurology. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Corporate Venture Arm Invests in Repurposed Drugs and New Combinations in CNS & Respiratory Disease Indications

7 Jun

A venture capital arm of a global pharmaceutical based in India was established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm also has an in-licensing arm and a specialty products incubator. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

7 Jun

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Joint Initiative Launched by a Leading Pharma and VC Firm Invests in Digital Health Companies with USA Focus

7 Jun

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.